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Abstract 
BACKGROUND: Direct implantation of metallic drug-eluting stents is recommended for lesions with high 
thrombotic burden; however, this can't be applied to bioresorbable scaffold for which adequate lesion preparation 
is recommended.  
AIM: We aimed at assessing the feasibility and safety of direct scaffold implantation based only on angiographic 
assessment in patients presented with non-ST segment elevation acute coronary syndrome. 
METHODS: The study was a retrospective two-centre study conducted over patients diagnosed with NSTE-ACS 
presented to cardiology department at Juan Ramon Hospital, Spain and critical care department, Cairo University 
in the period between February 2016 to May 2017. We included patients for whom we depend only on 
angiographic assessment for decision making whether to directly implant the scaffold or predilate the lesion and 
we excluded patients for whom intracoronary imaging was used at the index procedure either for pre or post-
implantation. The primary outcome of interest was the device-oriented composite endpoints (DOCE) including 
cardiac death, and MI attributed to the target vessel and TLR. The secondary endpoints were the broader patient-
oriented composite outcome (POCE) and scaffold/stent thrombosis. POCE includes all-cause mortality, any MI 
and any revascularisation (including TLR, TVR and revascularisation of non- target vessel) 
RESULTS: Among 46 patients with NSTE-ACS treated with BVS, we did direct implantation in 20 patients (group 
A), and we used pre dilatation in 26 patients (group B). The two groups have similar demographics and clinical 
criteria. Procedural success was obtained in all study population. Mean follow up duration was 12 months. We 
have total of 10% device-oriented composite endpoints in group A versus 15% in group B (p-value = 0.684). We 
didn’t document any cardiac death in both groups. In group B we had one (3.8%) non-fatal MI while there was no 
MI in group A (P-value = 1). In group A we had 2 cases (10%) of TLR while in group B there were 3 cases 
(11.5%) TLR (P-value = 1). We have two cases (7.7%) of TVR in group B and one in group A p-value = 1. All 
cases were planned staged PCI. Scaffold thrombosis occurred in one case in group A (5%) and two cases in 
group B (7.7%) p-value = 1. 
CONCLUSION: With proper lesion selection, direct BVS implantation in all-comers NSTE-ACS patients is feasible 
and safe even without the aid of intracoronary imaging. 
 
 
 
 
Introduction 
 
Despite that drug-eluting stents (DES) with 
biocompatible or biodegradable polymers have a 
considerably improved safety profile and considered a 
standard of care for patients with coronary artery 
disease [1], [2], bioresorbable stents, commonly 
referred to as scaffolds, can provide support to the 
vessel wall for a defined period after angioplasty but 
are subsequently resorbed [3]. 
Current recommendation for the 
bioresorbable vascular scaffold (BRS) implantation is 
plaque preparation with adequate pre dilatation [4], [5] 
however in the setting of large thrombus burden like 
patients with acute coronary syndrome (ACS), 
aggressive pre dilatation may result in an increased 
risk of distal embolization and subsequent flow 
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deterioration [6]. 
Moreover, the culprit lesion in both groups 
has different morphologic patterns. Lesions in ST-
segment elevation myocardial infarction (STEMI) 
tends to be softer, more lipid-rich, with thinner cap 
with more thrombotic burden mainly red thrombus [7] 
making them an ideal substrate for the BRS which is 
not the case for the non-ST segment elevation ACS 
(NSTE-ACS). NSTE-ACS represents a challenging 
subset in which BRS is under-investigated. 
On the other hand, precise vessel/scaffold 
sizing should be performed, preferably with optical 
coherence tomography (OCT), which also allows 
accurate assessment of scaffold apposition [8]. 
However, in the setting of all-comers ACS patients 
intracoronary imaging may not be available especially 
in low- and middle-income countries. We aimed at 
assessing the feasibility and safety of direct scaffold 
implantation based only on angiographic assessment 
in a high-risk group of patients (NSTE-ACS). 
 
 
Methods 
 
The current study was a retrospective two-
centre study conducted over patients diagnosed with 
NSTE-ACS presented to cardiology department at 
Juan Ramon Hospital, Spain and critical care 
department, Cairo University in the period between 
February 2016 to May 2017. 
We included patients for whom we depend 
only on angiographic assessment for decision making 
whether to directly implant the scaffold or predilate the 
lesion and we excluded patients for whom 
intracoronary imaging whether intravascular 
ultrasound (IVUS) or OCT were used at the index 
procedure either for pre or post-implantation. 
We used the ABSORB (Abbott Vascular, 
Santa Clara, CA, USA), the second-generation 
device, BVS 1.1 which is an everolimus-eluting BRS 
composed of Poly-L-lactic acid (PLLA) and Poly-D, L-
lactic acid (PDLLA), designed in in-phase zigzag 
hoops linked by bridges 
When pre dilatation was attempted it was 
done with balloon 0.5 mm smaller or equal to scaffold 
device recommended. In the second group direct 
scaffold implantation was done. Deployment of the 
scaffold was done with slow increase of two 
atmospheres every five seconds until the scaffold is 
completely expanded. The pressure is maintained for 
30 seconds. Post-dilatation, when attempted, was 
done with non-compliant balloon at high pressure (> 
16 atm) and the dilatation limit was 0.5 mm above the 
nominal diameter.  
Clinical follow-up was obtained by the clinical 
visit and/or through telephone contact, according to a 
schedule specific for each site. Major adverse cardiac 
events were collected at discharge and the end of the 
follow-up period. The primary outcome of interest was 
the device-oriented composite endpoints (DOCE) 
including cardiac death; MI attributed to the target 
vessel and TLR [9]. The secondary endpoints were 
the broader patient-oriented composite outcome 
(POCE) and scaffold/stent thrombosis. POCE 
includes all-cause mortality, any MI and any 
revascularisation (including TLR, TVR and 
revascularisation of non- target vessel) [9]. MI 
definitions were based on the most recent universal 
definition of MI [10]. All deaths were considered 
cardiac unless proven otherwise. Stent/scaffold 
thrombosis definitions were based on the Academic 
Research Consortium (ARC) criteria [9].  
Data were coded and entered using the 
statistical package SPSS (Statistical Package for the 
Social Sciences) version 25. Data were summarised 
using mean, standard deviation, median, minimum 
and maximum in quantitative data and using 
frequency (count) and relative frequency (percentage) 
for categorical data. Comparisons between 
quantitative variables were made using the non-
parametric Mann-Whitney test [11]. For comparing 
categorical data, Chi-square (2) test was performed. 
Exact test was used instead when the expected 
frequency is less than 5 [12]. P-values less than 0.05 
were considered as statistically significant.  
 
 
Results 
 
From whole patients who received at least 
one BVS during the mentioned period, forty-six patient 
were enrolled in our study. Those patients received at 
least one BVS depending on visual assessment of the 
angiography without the aid of any intracoronary 
imaging modality during the index procedure. 
Table 1: Clinical characteristics 
 Direct 
(20) 
Predilatation 
(26) 
P value 
Patient Characteristics 
Age 49.85 ± 9.16 52.50 ± 7.40 0.602 
Male sex 16 (80.0%) 17(65.4%) 0.275 
Smoking 15 (75.0%) 20 (76.9%) 1 
Obesity 2 (10.0%) 3 (11.5%) 1 
Dyslipidemia 6 (30.0%) 9 (34.6%) 0.741 
Hyperuricemia 1 (5.0%) 1 (3.8%) 1 
Hypertension 5 (25.0%)0 9 (34.6%) 0.482 
DM 3 (15.0%) 3 (11.5%) 1 
Family history of IHD 0 1 (3.8%) 1 
Clinical Presentation and management 
TIMI risk score 1.9 ± 0.91 2.0 ± 0.85 0.885 
Admission 
diagnosis 
Unstable 
angina 
9 (45.0%) 13 (50.0%) 0.736 
NSTEMI 11 (55.0%) 13 (50.0%) 
Early invasive strategy 15 (75.0%) 21 (80.8%) 0.726 
Elective strategy 5 (25.0%) 5 (19.2%) 
Single vessel disease 17 (85.0%) 20 (76.9%) 0.711 
MVD 3(15.0%) 6 (23.1%) 
 
The enrolled patients were divided into two 
groups. Group A included 20 patients who received 
direct scaffold implantation and group B included 26 
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patients in which pre dilatation was done. Patients' 
demographics, clinical data and risk factors were 
nearly similar in both groups as shown in Table 1. In 
group A 11 patients (55%) had NSTEMI and 9 
patients (45%) had unstable angina, while in group B 
NSTEMI represent 50% (13 patients) and UA 
represent 50% (13 patients), P = value 0.736. Group 
A has TIMI risk score of 1.9 ± 0.91 as compared to 
group B 2.0 ± 0.85, P-value = 0.885. Post-dilatation 
was done in 90% of patients in group A and 88% of 
group B, p-value = 1. Angiographic and procedural 
data are presented in Table 2.  
Table 2: Angiographic and procedural data 
Target 
vessel 
LAD 16 (69.6%) 19 (57.6%) 0.453 
LCX 4 (17.4%) 6 (18.2%) 
RCA 3 (13.0%) 8 (24.2%) 
Post-dilatation 18 (90.0%) 23 (88.5%) 1 
Scaffold size, mm 3.23 ± 0.25 3.04 ± 0.33 0.018 
Scaffold length, mm 18.15 ± 6.06 20.45 ± 6.25 0.140 
Dissection 1 (5.0%) 4 (15.4%) 0.369 
Slow flow 1 (5.0%) 0 (0.0%) 0.435 
No re-flow 1 (5.0%) 0 (0.0%) 0.435 
Stent thrombosis 0 (0%) 0 (0%) ---- 
Side-branch compromise 3 (15%) 6 (23.1%) 0.711 
 
Procedural success was obtained in all study 
population. Offline QCA analysis was done for all 
patients and data are presented in Table 3. Immediate 
clinical success was achieved in all cases. There was 
no significant difference between procedural 
complications in both groups.  
Table 3: QCA data 
 
QCA 
Direct Predilatation P-value 
MLD 1.15 ± 0.31 0.94 ± 0.29 0.008 
RVD 3.02 ± 0.44 2.83 ± 0.46 0.171 
DS % 61.74 ± 11.41 65.47 ± 10.99 0.170 
Acute gain 1.25 ± 0.38 1.17 ± 0.48 0.880 
Late loss 0.52 ± 0.53 -0.65 ± 3.46 0.210 
Late loss index 36.57 ± 24.59 39.43 ± 48.47 0.607 
 
Edge dissection occurred in one patient (5%) 
in group A and 4 patients (15.4%) in group B, p-value 
0.369. Slow flow and no-reflow occurred in 2 patients 
in group A yet this was statistically insignificant, p-
value = 0.435. Side branch compromise occurred in 3 
patients (15%) in group A and in 6 patients (23%) in 
group B p-value = 0.945. Those who had chest pain or 
impaired TIMI flow were treated with either balloon 
dilatation in side-branch ostium or final kissing 
inflation. We didn’t document any in-hospital major 
adverse events. Mean FU duration of this group was 
12 months. Angiographic follow up was done in 7 
patients in group A (35%) while in group B 
angiographic follow up was done in 14 patients (53%) 
P-value = 0.451. During the whole FU period, there 
was a lower incidence of both device-oriented and 
patient-oriented composite endpoints in the direct 
implantation group (group A), yet this was statistically 
insignificant (Table 4). DOCE occurred in 10% in 
group A and in 15% in group B (p-value = 0.684). 
POCE occurred in 15% in group A and 23% in group 
B (p-value = 0.711). We didn’t document any cardiac 
death in both groups. In group B we had one (3.8%) 
non-fatal MI while there was no MI in group A (P-value 
= 1). In group A we had 2 cases (10%) of TLR while in 
group B there were 3 cases (11.5%) TLR (P-value = 
1). One case of TLR in group A was due to very late 
definite scaffold thrombosis and was treated with 
DES. The other case underwent an OCT which 
revealed ISR with neoatherosclerosis and was treated 
with another scaffold. In group B one case of TLR was 
also due to late thrombosis and was treated with DES. 
OCT of the second case revealed diffuse intimal 
hyperplasia and was treated with scoring balloon 
followed by a drug coating balloon (DCB) angioplasty, 
and the third case has neoatherosclerosis and was 
treated with DES. We have two cases (7.7%) of TVR 
in group B and one in group A p-value = 1. All cases 
were planned staged PCI.  
Scaffold thrombosis occurred in one case in 
group A (5%) and two cases in group B (7.7%) p 
value = 1. In group A the patient presented with UA, 
OCT under expanded struts which treated with 
aggressive post dilatation, intracoronary GPIIb-IIIa 
inhibitor and DES. In group B one patients with late 
scaffold thrombosis presented with STEMI three days 
after discontinuation of the Aspirin. Primary PCI was 
done with implantation of a DES. The other patient 
presented with recurrent chest pain and his OCT 
revealed proximal edge dissection that was treated 
with implantation of another scaffold.  
Table 4: Outcome 
Composite end points 
 Direct Predilatation P value 
Death 0 0 --- 
MI 0 1 (3.8%) 1 
TLR 2 (10%) 3 (11.5%) 1 
TVR 1 (5%) 2 (7.7%) 1 
ST 1(5%) 2 (7.7%) 1 
 
 
 
Discussion 
 
In the setting of emergency PCI to an ACS 
patient using the BVS the operators will be faced with 
too difficult decisions. First, whether to predilate the 
lesion as recommended for this specific device or to 
directly implant the scaffold as preferred in lesions 
with high thrombotic burden. The second difficult 
scenario is about the appropriate sizing of the scaffold 
and sizing of the balloons for pre and post dilatation if 
intracoronary imaging is not available which is a 
common scenario in all-comers ACS patients due to 
high cost or limited availability. 
There is no solid data to support decision 
making in this difficult scenario. Several studies 
showed that direct implantation of metallic DES is 
associated with the reduction of flow disturbances 
after primary PCI, better ST-segment resolution as 
well as better survival at 30 days and one year [13], 
[14], [15], [16]. 
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However, in the BVS where pre dilatation is 
highly recommended, data about feasibility and safety 
of direct scaffold implantation is so limited to give 
strong evidence for decision making. 
Adding to the difficulty, the spectrum of ACS 
is not homogenous. The culprit lesion in STEMI 
versus NSTE-ACS has different morphologic patterns. 
Lesions in STEMI tends to be softer, more lipid-rich, 
with thinner cap with more thrombotic burden mainly 
red thrombus [7] making them an ideal substrate for 
BVS which is not the case for the NSTE-ACS.  
To the best of our knowledge, our study is the 
first one to evaluate the immediate and one-year 
outcome of direct BVS implantation in a cohort of 
patient with NSTE-ACS based only on angiographic 
assessment without use of intracoronary imaging. We 
achieved procedural and clinical success in all 
patients. We didn’t report any in-hospital adverse 
events. At 12 months follow up there was no 
significant difference between direct implantation 
group and pre dilatation group as regard composite 
endpoints or scaffold thrombosis.  
Rzeszutko et al., [17] reported the in-hospital 
outcome of 50 ACS patients who received direct 
scaffold implantation. NSTEMI represent 62 % of their 
study population. They also didn’t use OCT for sizing. 
They didn’t report any in-hospital MI, scaffold 
thrombosis or TLR but long-term data were not 
reported.  
Suarez de Lezo et al., [18] studied the 
outcome of direct scaffold implantation and reported a 
5.9% MACE rate 12 months. They reported 0.6% 
death due scaffold thrombosis and 4% TLR however 
there was no significant difference between direct 
implantation group and pre dilatation group. 
Importantly they use intracoronary Imaging (IVUS or 
OCT) in nearly 86%of lesions which allow better sizing 
and ensure good scaffold apposition. 
In the BVS-STEMI-STRATEGY-IT study, 
Alfonso Ielasi et al., [19] evaluate the 30-day outcome 
of BVS in STEMI patients using pre-specified strategy. 
The strategy involved using direct implantation only 
when there is TIMI 2-3 flow after wiring the culprit 
lesion and/or after thrombus aspiration and only when 
the residual stenosis is less than 30%. Otherwise, pre-
dilatation was done. They reported DOCE 0.6% (0.4% 
death and 0.2% TLR) and scaffold thrombosis in 
0.2%. The used intracoronary imaging before 
implantation in 26% of cases and at least after 
implantation in 52% of cases. 
The most important finding of our study is the 
feasibility and good midterm outcome of direct BVS 
deployment in patients with NSTE-ACS. The value of 
an angiographic assessment of a scaffold invisible for 
fluoroscopy was supposed to be limited and does not 
provide information about the scaffold apposition. 
However, this was disproven by our results. However, 
it is not a randomised study, the study sample size is 
relatively small, and the results only allow for raising a 
new principle that needs larger randomised studies to 
prove.  
In conclusion, with proper lesion selection, 
direct BVS implantation in all-comers NSTE-ACS 
patients is feasible and safe even without the aid of 
intracoronary imaging. 
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